InspireMD has completed enrolling patients for MGuard for Acute ST Elevation Reperfusion (MASTER) trial.
The controlled, multinational and randomized trial is designed to compare Mguard and MGuard prime coronary stents with the standard bare metal stents (BMS) or drug eluting stents (DES), for acute ST-elevation myocardial infarction (STEMI) patients.
The primary endpoint is complete ST segment resolution, while secondary endpoints such as thrombolysis in myocardial infarction flow, myocardial blush grade and major adverse cardiac events will be measured.
The company said clinical follow-up will continue for one year.
InspireMD research and development CTO and vice president Eli Bar said the enrollment has been completed one month ahead of schedule.
"Completion of the MASTER trial is a key component of our plan to establish MGuard as the standard of care for Acute MI patients," Bar added.
The company is looking forward to release preliminary results in the third quarter of 2012.
MGuard features a combination of a coronary stent with an embolic protection specifically designed for use in acute MI patients, providing lifelong embolic protection, without affecting deliverability.